ArticleFrontiers in oncology2022

Case report: Conversion therapy for advanced intrahepatic cholangiocarcinoma using PD-1 inhibitor plus S-1 and nab-paclitaxel.

Xiaocheng Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.